Cancer is increasingly becoming a highly manageable disease

In the Sunday edition of To Vima newspaper and Vita magazine (25 January 2026), the views of Ms Evangeli Bista, co-founder of Kapa3, were featured, shedding light on the landscape of modern oncology and the challenges emerging within the current Greek healthcare reality.

Ms Bista addressed the Greek context and highlighted the importance of digital technology as a cornerstone of modern health policy, particularly in the field of cancer care, where treatment pathways are complex, long-term, and deeply person-centred. As she noted, Greece has already made measurable progress: electronic and paperless prescribing, oncology registries, the National Electronic Health Record, and applications such as MyHealthApp are creating the conditions for more coordinated and transparent care. When healthcare professionals, as well as patients themselves, are equipped with appropriate digital skills, patient autonomy is strengthened, treatment outcomes improve, and inequalities—especially those affecting vulnerable population groups—are reduced.

The article is co-authored by distinguished scientists and collaborators: Maria Gazouli, Professor of Biology, Genetics and Nanomedicine at the Medical School of the National and Kapodistrian University of Athens and national representative on the Committee for Advanced Therapies of the European Medicines Agency; Manolis Saloustros, Associate Professor of Oncology at the University of Thessaly and President of the Hellenic Society of Medical Oncology (HESMO); and Christos Frantzidis, Assistant Professor of Informatics and Machine Learning at the University of Lincoln in the United Kingdom.

The contributing experts underline that modern oncology increasingly approaches cancer as a largely manageable chronic disease, through targeted and personalised therapies. The use of innovative technologies—such as next-generation sequencing, mRNA vaccines, PARP inhibitors and cellular therapies—has significantly expanded therapeutic options. At the same time, prognosis is becoming more dynamic and individualised through the use of multi-omics profiling, machine learning algorithms and liquid biopsy techniques. Particular emphasis is placed on the early integration of palliative care and psychosocial support, which play a crucial role in improving patients’ quality of life. Finally, the importance of structured and coordinated healthcare services is highlighted, with the medical oncologist acting as a key coordinator of person-centred care.

Beyond documenting technological advances, the article opens a broader discussion on the digital transition in oncology care, addressing issues of access, meaningful use of data and the need for coordination across different scientific disciplines. Digital health is presented not as an end in itself, but as a tool that requires collaboration, institutional maturity and a shared vision in order to deliver real value to patients.

The overarching message is clear: every step, whether small or large, matters. Progress in oncology is not the result of isolated actions, but of collective effort. Through collaboration among scientists, healthcare professionals, organisations and patients, the conditions for meaningful and sustainable change can be created—always with the human being and their real needs at the centre.

Text / Adaptation: Ifiyenia Anastasiou for Kapa3

Dispensing High-Cost Medicines (HCM) Through Private Pharmacies – What Changes for Patients

A recent Ministerial Decision (Government Gazette B’ 6333/27.11.2025) introduces significant changes to the distribution of High-Cost Medicines (HCM), allowing patients to receive these medicines not only from EOPYY pharmacies but also from private community pharmacies. This new framework replaces the 2020 regulation and aims to ease patient access, reduce inconvenience, and improve the delivery of essential therapies.

The list of HCM medicines included in this process is available in the corresponding Government Gazette here.

What Changes for Patients

  • The prescribing physician issues the prescription through the national e-prescription system (IDIKA).
  • Patients may choose to receive their medicine either from an EOPYY pharmacy or a private community pharmacy.
  • Through the dedicated HCM application (using Taxisnet credentials + AMKA), patients select the private pharmacy that will serve them.
  • Patients receive electronic notifications regarding the status of their order and the availability of the medicine for pickup.
  • Medicines are dispensed with zero patient co-payment.
  • The time from approval to pickup may not exceed 10 days.

What Changes for Private Pharmacies

Private pharmacists now assume an expanded role in handling High-Cost Medicines, with specific responsibilities and procedures.

  1. Medicine Receipt
  • The pharmacist scans the product’s barcode in the EOPYY system to complete the warehouse reconciliation process for EOPYY’s pharmaceutical depot.
  • The patient is automatically notified via the system once the medicine arrives at the pharmacy.
  1. Prescription Verification and Dispensing

The pharmacist must verify:

  • the patient’s identity or the presence of a valid authorization,
  • the accuracy of the prescription and its alignment with the prescribing physician’s instructions,
  • the correct medicinal product,
  • the presence of any required supporting documents,
  • the authenticity labels or deactivated safety features,
  • the physician’s signature and the recipient’s signature.

The pharmacist then signs and stamps the prescription to complete the dispensing process.

Failure to comply with these procedures may lead to sanctions under Presidential Decree 121/2008.

  1. Pharmacist Remuneration

For each dispensed HCM prescription, pharmacists receive:

  • a scientific service fee of €20.00 + VAT,

without the need to issue transport documents.

This cost is not included in the total pharmaceutical expenditure ceiling of EOPYY.

  1. Monthly Submission of Prescriptions

Every month, pharmacists must send:

  • the dispensed prescriptions,
  • the consolidated report,
  • and the service invoice
    to the EOPYY Department of Prescription Processing and Review.

Electronic images of prescriptions remain available for audit.

  1. Unexecuted Prescriptions

If a prescription is not executed:

  • the medicine is returned to the pharmaceutical company after 5 days,
  • and the company issues a credit invoice to EOPYY.
  1. Loss or Damage of Medicines

If the medicine is lost or damaged due to pharmacist responsibility,
EOPYY charges the pharmacist the procurement value of the product.

Why This Change Matters

The updated system:

  • reduces patient inconvenience,
  • relieves congestion in EOPYY pharmacies,
  • ensures faster access to essential therapies,
  • strengthens the role of community pharmacists,
  • and modernizes the distribution of High-Cost Medicines.

This development significantly improves the daily lives of patients who rely on regular access to specialized treatments — including many oncology patients. KAPA3 continues to stand by cancer patients and their families, offering reliable guidance and practical support so that every patient feels safe and fully informed about their rights and benefits.

Text/Adaptation: Ifiyenia Anastasiou for Kapa3